Tags : Protein Degradation Therapies


Vertex Signs a 4 Years Agreement with Kymera to Discover

Shots: Kymera to receive $70M upfront including equity investment, >$1B as development, regulatory & commercial milestones for up to 6 therapies opted by Vertex, royalties on sales of products and is responsible for clinical research activities. Vertex to get an option to license the developed molecules against designated targets The focus of the collaboration is […]Read More